Inovio Pharmaceuticals Inc (INO)

[biovalidator]

HEP C News from INO affiliate in Korea:

VGX Inter (KOSPI: 011000) "Over the past 22 days, Keimyung University School of Medicine opened in 2014 between the Association for Single Topic Symposium Proceedings of the company through the research and development of DNA vaccines in the treatment of chronic hepatitis C (VGX-6150) for clinical research content was introduced, "he said.


Recent advances in the treatment of viral hepatitis, the theme of the symposium conducted geumbeon heojeong professor at Pusan ??National University College of Medicine, Section of new chronic hepatitis C treatment, a therapeutic vaccine (VGX-6150) entitled "Current progress in using electric drilling machines VGX-6150 DNA vaccine therapy clinical trial for safety evaluation for Phase 1 multicenter, open, progress in the form of increased capacity, the new treatment of chronic hepatitis C is the expectation, "he said.


Professor heojeong announcement, "VGX International clinical trials being developed in the treatment of chronic hepatitis C DNA vaccine (VGX-6150) is the most difficult to treat existing standard treatments first genotypes (1a, 1b) of the amino acid sequence of the virus database analyzing the antigen within the amino acid common sequence to find and enhanced the maximum concordance between the virus, antigens for inducing immune responses to a wide range of amino acid sequences were selected as "high balhimyeo" Thus produced DNA vaccine (VGX-6150) is 1000 times the incidence antigen, the immune response induced by 100-fold increase in the electroporation method has the characteristics of high efficiency, the body passed to the already confirmed non-clinical safety and efficacy in a bar, "he said.


Inter VGX DNA vaccine treatment of chronic hepatitis C (VGX-6150) of the hepatitis C virus NS3/4A, NS4B, NS5A antigen and adjuvant for the expression of IL-28B and a plasmid containing a mixture of nucleic acid sequences, the antigen -specific T cell immune response by inhibiting the replication of hepatitis C virus or hepatitis C virus-infected hepatocytes is removed.


People infected with the hepatitis C virus all over the world as of 2005 about 2.8 percent of the approximately 185 million people are estimated to Central Asia, including Mongolia, China, Pakistan, Thailand and elsewhere in Southeast Asia, Egypt wisihan North Africa is relatively often infected.


Treatment of chronic hepatitis C $ 3 billion global market scale in 2012, but now has $ 20 billion in 2020 and is forecast to grow to scale, such as a recent DAA, even if treated with the antiviral drug interferon resistance by conventional formulations tend to come back again , no side effects, such as hepatitis C DNA vaccine treatment of autoimmune therapeutics are emerging as clinical need.

http://www.vgxi.com/bbs/bbs/board.php?bo_table=news&wr_id=344